Reply
Mingjiang Xu, Dechun Feng, Bin Gao – 5 June 2015
Pure laparoscopic management of early biliary leakage after liver transplantation: Abdominal lavage and T‐Tube placement
Ailton Sepulveda, Raffaele Brustia, Fabiano Perdigao, Olivier Soubrane, Olivier Scatton – 4 June 2015
Pretransplant management of basilar artery aneurysm and moyamoya disease in a child with Alagille syndrome
Marco Pavanello, Mariasavina Severino, Lorenzo D'Antiga, Lucio Castellan, Angela Calvi, Michele Colledan, Carlo Gandolfo – 4 June 2015
Hepatocellular carcinoma surveillance in hepatitis B virus–infected individuals: Who and how?
Ka‐Kit Li, Palak J. Trivedi, Sophie Von Heimendahl, Tony Bruns, Steve T. Ward, Ye Oo, David Mutimer – 4 June 2015
Thrombolytic protocol minimizes ischemic‐type biliary complications in liver transplantation from donation after circulatory death donors
Laura C. Burlage, Shanice A. Karangwa, Ton Lisman, Paulo N. A. Martins, Robert J. Porte – 4 June 2015
Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis
James H. Tabibian, Steven P. O'Hara, Christy E. Trussoni, Pamela S. Tietz, Patrick L. Splinter, Taofic Mounajjed, Lee R. Hagey, Nicholas F. LaRusso – 4 June 2015 – Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, fibroinflammatory cholangiopathy. The role of the microbiota in PSC etiopathogenesis may be fundamentally important, yet remains obscure. We tested the hypothesis that germ‐free (GF) mutltidrug resistance 2 knockout (mdr2−/−) mice develop a distinct PSC phenotype, compared to conventionally housed (CV) mdr2−/− mice.
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation
Quirino Lai, Jan Lerut, For the European Hepatocellular Cancer Liver Transplant (EurHeCaLT) Study Group – 4 June 2015
A novel, minimally invasive technique for management of peristomal varices
James H. Tabibian, Barham K. Abu Dayyeh, Gregory J. Gores, Michael J. Levy – 4 June 2015
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated Cirrhosis
Varun Saxena, Lisa Nyberg, Marypat Pauly, Aditi Dasgupta, Anders Nyberg, Barbara Piasecki, Bradley Winston, Jacquelyn Redd, Joanna Ready, Norah A. Terrault – 1 June 2015 – Risks and benefits of simeprevir plus sofosbuvir (SIM+SOF) in patients with advanced cirrhosis are unknown. We assessed the safety and sustained virological responses (SVR) of SIM+SOF with and without ribavirin (RBV) in patients with Child‐Pugh (CP)‐B/C versus CP‐A cirrhosis and compared to matched untreated controls.